Company Legal Name
Latest Valuation
Founded Year
Headquarters
Cambrian Biopharma Inc. develops innovative therapeutics targeting the biological mechanisms of aging and age-related diseases. Founded in 2019 and headquartered in New York, the biotechnology company focuses on addressing fundamental aging processes rather than individual age-related conditions. Cambrian's approach represents a paradigm shift in healthcare, moving beyond traditional disease treatment to target the underlying drivers of aging itself. The company operates in the emerging longevity biotechnology sector, which has gained significant investor and scientific interest as populations age globally. Cambrian continues advancing its pipeline of aging-targeted therapeutics through preclinical and clinical development programs.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
